Cargando…
A high-throughput expression screening platform to optimize the production of antimicrobial peptides
BACKGROUND: Antimicrobial peptides (AMPs) are promising candidates for the development of novel antibiotics, but it is difficult to produce sufficient quantities for preclinical and clinical studies due to their toxicity towards microbial expression hosts. To avoid laborious trial-and-error testing...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307881/ https://www.ncbi.nlm.nih.gov/pubmed/28193216 http://dx.doi.org/10.1186/s12934-017-0637-5 |
_version_ | 1782507452925739008 |
---|---|
author | Schreiber, Christine Müller, Hagen Birrenbach, Oliver Klein, Moritz Heerd, Doreen Weidner, Tobias Salzig, Denise Czermak, Peter |
author_facet | Schreiber, Christine Müller, Hagen Birrenbach, Oliver Klein, Moritz Heerd, Doreen Weidner, Tobias Salzig, Denise Czermak, Peter |
author_sort | Schreiber, Christine |
collection | PubMed |
description | BACKGROUND: Antimicrobial peptides (AMPs) are promising candidates for the development of novel antibiotics, but it is difficult to produce sufficient quantities for preclinical and clinical studies due to their toxicity towards microbial expression hosts. To avoid laborious trial-and-error testing for the identification of suitable expression constructs, we have developed a small-scale expression screening platform based on a combinatorial plasmid library. RESULTS: The combinatorial library is based on the Golden Gate cloning system. In each reaction, six donor plasmids (each containing one component: a promoter, fusion partner 1, fusion partner 2, protease cleavage site, gene of interest, or transcriptional terminator) were combined with one acceptor plasmid to yield the final expression construct. As a proof of concept, screening was carried out in Escherichia coli and Pichia pastoris to study the expression of three different model AMPs with challenging characteristics, such as host toxicity or multiple disulfide bonds. The corresponding genes were successfully cloned in 27 E. coli and 18 P. pastoris expression plasmids, each in a one-step Golden Gate reaction. After transformation, small-scale expression screening in microtiter plates was followed by AMP quantification using a His(6) tag-specific ELISA. Depending on the plasmid features and the expression host, the protein yields differed by more than an order of magnitude. This allowed the identification of high producers suitable for larger-scale protein expression. CONCLUSIONS: The optimization of recombinant protein production is best achieved from first principles by initially optimizing the genetic construct. The unrestricted combination of multiple plasmid features yields a comprehensive library of expression strains that can be screened for optimal productivity. The availability of such a platform could benefit all laboratories working in the field of recombinant protein expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-017-0637-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5307881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53078812017-03-13 A high-throughput expression screening platform to optimize the production of antimicrobial peptides Schreiber, Christine Müller, Hagen Birrenbach, Oliver Klein, Moritz Heerd, Doreen Weidner, Tobias Salzig, Denise Czermak, Peter Microb Cell Fact Research BACKGROUND: Antimicrobial peptides (AMPs) are promising candidates for the development of novel antibiotics, but it is difficult to produce sufficient quantities for preclinical and clinical studies due to their toxicity towards microbial expression hosts. To avoid laborious trial-and-error testing for the identification of suitable expression constructs, we have developed a small-scale expression screening platform based on a combinatorial plasmid library. RESULTS: The combinatorial library is based on the Golden Gate cloning system. In each reaction, six donor plasmids (each containing one component: a promoter, fusion partner 1, fusion partner 2, protease cleavage site, gene of interest, or transcriptional terminator) were combined with one acceptor plasmid to yield the final expression construct. As a proof of concept, screening was carried out in Escherichia coli and Pichia pastoris to study the expression of three different model AMPs with challenging characteristics, such as host toxicity or multiple disulfide bonds. The corresponding genes were successfully cloned in 27 E. coli and 18 P. pastoris expression plasmids, each in a one-step Golden Gate reaction. After transformation, small-scale expression screening in microtiter plates was followed by AMP quantification using a His(6) tag-specific ELISA. Depending on the plasmid features and the expression host, the protein yields differed by more than an order of magnitude. This allowed the identification of high producers suitable for larger-scale protein expression. CONCLUSIONS: The optimization of recombinant protein production is best achieved from first principles by initially optimizing the genetic construct. The unrestricted combination of multiple plasmid features yields a comprehensive library of expression strains that can be screened for optimal productivity. The availability of such a platform could benefit all laboratories working in the field of recombinant protein expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-017-0637-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-13 /pmc/articles/PMC5307881/ /pubmed/28193216 http://dx.doi.org/10.1186/s12934-017-0637-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Schreiber, Christine Müller, Hagen Birrenbach, Oliver Klein, Moritz Heerd, Doreen Weidner, Tobias Salzig, Denise Czermak, Peter A high-throughput expression screening platform to optimize the production of antimicrobial peptides |
title | A high-throughput expression screening platform to optimize the production of antimicrobial peptides |
title_full | A high-throughput expression screening platform to optimize the production of antimicrobial peptides |
title_fullStr | A high-throughput expression screening platform to optimize the production of antimicrobial peptides |
title_full_unstemmed | A high-throughput expression screening platform to optimize the production of antimicrobial peptides |
title_short | A high-throughput expression screening platform to optimize the production of antimicrobial peptides |
title_sort | high-throughput expression screening platform to optimize the production of antimicrobial peptides |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307881/ https://www.ncbi.nlm.nih.gov/pubmed/28193216 http://dx.doi.org/10.1186/s12934-017-0637-5 |
work_keys_str_mv | AT schreiberchristine ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT mullerhagen ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT birrenbacholiver ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT kleinmoritz ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT heerddoreen ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT weidnertobias ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT salzigdenise ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT czermakpeter ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT schreiberchristine highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT mullerhagen highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT birrenbacholiver highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT kleinmoritz highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT heerddoreen highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT weidnertobias highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT salzigdenise highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides AT czermakpeter highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides |